The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

Inclusion Criteria:

• Age over 18
• Able to give informed consent
• On the waiting list for heart transplant
• Left Ventricular Dysfunction awaiting catheterisation

Exclusion Criteria:

• Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin
• Women of child bearing age and breast feeding women
• Cardiac pacemaker or other implanted metallic device
• Unable to give informed consent